These findings suggest that inhibition of IL-17A has no significant effect on early reparative fibrosis post-myocardial infarction, but can markedly inhibit excessive fibrosis post-myocardial infarction, thereby improving cardiac function and prognosis (8). The gene discussed is IL17A; the disease is myocardial infarction.